155 related articles for article (PubMed ID: 15749424)
1. Functional imaging of a large demyelinating lesion.
Padma MV; Adineh M; Pugar K; Mukherjee J; Satter M; Shi B; Dunigan K; Bidwell K; Ezzeddine B; Mantil J
J Clin Neurosci; 2005 Feb; 12(2):176-8. PubMed ID: 15749424
[TBL] [Abstract][Full Text] [Related]
2. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET.
Takenaka S; Shinoda J; Asano Y; Aki T; Miwa K; Ito T; Yokoyama K; Iwama T
Brain Tumor Pathol; 2011 Jul; 28(3):229-38. PubMed ID: 21442242
[TBL] [Abstract][Full Text] [Related]
3. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
4. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
5. Tumefactive Demyelinating Lesion Differentiated from a Brain Tumor Using a Combination of Magnetic Resonance Imaging and (11)C-methionine Positron Emission Tomography.
Ninomiya S; Hara M; Morita A; Teramoto H; Momose M; Takahashi T; Kamei S
Intern Med; 2015; 54(11):1411-4. PubMed ID: 26027998
[TBL] [Abstract][Full Text] [Related]
6. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study.
Bolcaen J; Acou M; Mertens K; Hallaert G; Van den Broecke C; Achten E; Goethals I
J Neuroimaging; 2013 Jul; 23(3):431-6. PubMed ID: 23279326
[TBL] [Abstract][Full Text] [Related]
7. Frontal Tumefactive Demyelinating Lesion Mimicking Glioblastoma Differentiated by Methionine Positron Emission Tomography.
Yasuda S; Yano H; Kimura A; Suzui N; Nakayama N; Shinoda J; Iwama T
World Neurosurg; 2018 Nov; 119():244-248. PubMed ID: 30114544
[TBL] [Abstract][Full Text] [Related]
8. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
Majima H; Ito T; Koyama N
Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
[TBL] [Abstract][Full Text] [Related]
9. Sequential proton MRS study of brain metabolite changes monitored during a complete pathological cycle of demyelination and remyelination in a lysophosphatidyl choline (LPC)-induced experimental demyelinating lesion model.
Degaonkar MN; Khubchandhani M; Dhawan JK; Jayasundar R; Jagannathan NR
NMR Biomed; 2002 Jun; 15(4):293-300. PubMed ID: 12112612
[TBL] [Abstract][Full Text] [Related]
10. Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study.
Chiavazza C; Cistaro A; Fania P; Bertolotto A; Cavalla P; Rudà R; Pinessi L; Soffietti R
Neurol Sci; 2016 Dec; 37(12):2019-2023. PubMed ID: 27457655
[No Abstract] [Full Text] [Related]
11. Primary Central Nervous System Natural Killer Cell Lymphoma in a Chinese Woman with Atypical (11)C-Choline Positron Emission Tomography and Magnetic Resonance Spectrometry Findings.
Li LF; Taw BB; Pu JK; Hwang GY; Lui WM; Leung GK
World Neurosurg; 2015 Oct; 84(4):1176.e5-9. PubMed ID: 26142813
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of [
Hashimoto S; Inaji M; Nariai T; Kobayashi D; Sanjo N; Yokota T; Ishii K; Taketoshi M
Neurol Med Chir (Tokyo); 2019 May; 59(5):176-183. PubMed ID: 30996153
[TBL] [Abstract][Full Text] [Related]
13. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.
Arnold DL; Matthews PM; Francis GS; O'Connor J; Antel JP
Ann Neurol; 1992 Mar; 31(3):235-41. PubMed ID: 1637131
[TBL] [Abstract][Full Text] [Related]
14. [Metabolic imaging to follow stereotactic radiation of gliomas -- the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT].
Lichy MP; Henze M; Plathow C; Bachert P; Kauczor HU; Schlemmer HP
Rofo; 2004 Aug; 176(8):1114-21. PubMed ID: 15346287
[TBL] [Abstract][Full Text] [Related]
15. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
16. Functional imaging in Lhermitte-Duclose disease.
Padma MV; Jacobs M; Sequeira P; Adineh M; Satter M; Kraus G; Mantil JC
Mol Imaging Biol; 2004; 6(5):319-23. PubMed ID: 15380741
[TBL] [Abstract][Full Text] [Related]
17. [Abnormal scintigrams in demyelinating diseases of the brain (author's transl)].
Podreka I; Heiss WD; Jellinger K
Rofo; 1977 Dec; 127(6):550-4. PubMed ID: 146003
[TBL] [Abstract][Full Text] [Related]
18. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
[TBL] [Abstract][Full Text] [Related]
19. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.
Floeth FW; Pauleit D; Wittsack HJ; Langen KJ; Reifenberger G; Hamacher K; Messing-Jünger M; Zilles K; Weber F; Stummer W; Steiger HJ; Woebker G; Müller HW; Coenen H; Sabel M
J Neurosurg; 2005 Feb; 102(2):318-27. PubMed ID: 15739561
[TBL] [Abstract][Full Text] [Related]
20. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation.
Kwee SA; Coel MN; Lim J; Ko JP
J Neuroimaging; 2004 Jul; 14(3):285-9. PubMed ID: 15228773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
